Purpose
To evaluate the cellular and innate endpoints of an adenovirus vectored candidate HIV vaccine being evaluated in the trial IAVI-C114.
Grantee
Division
Global Health
Date
OCTOBER 2024
Region served
AFRICA
Committed amount
$1,818,185
Grant topic
HIV
Duration (months)
35
Grantee location
Cape Town, South Africa
Program strategy page
More about our work
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.